ATE471945T1 - Als medikament geeignete lösliche varianten des gp130-moleküls - Google Patents
Als medikament geeignete lösliche varianten des gp130-molekülsInfo
- Publication number
- ATE471945T1 ATE471945T1 AT06841152T AT06841152T ATE471945T1 AT E471945 T1 ATE471945 T1 AT E471945T1 AT 06841152 T AT06841152 T AT 06841152T AT 06841152 T AT06841152 T AT 06841152T AT E471945 T1 ATE471945 T1 AT E471945T1
- Authority
- AT
- Austria
- Prior art keywords
- soluble
- medication
- molecule used
- soluble variants
- polypeptide
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 102000004889 Interleukin-6 Human genes 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 abstract 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05028420A EP1801121A1 (en) | 2005-12-23 | 2005-12-23 | Soluble gp130 molecule variants useful as a medicament |
| PCT/EP2006/012515 WO2007071449A1 (en) | 2005-12-23 | 2006-12-22 | Soluble gp130 molecule variants useful as a medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE471945T1 true ATE471945T1 (de) | 2010-07-15 |
Family
ID=36233865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06841152T ATE471945T1 (de) | 2005-12-23 | 2006-12-22 | Als medikament geeignete lösliche varianten des gp130-moleküls |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7851182B2 (https=) |
| EP (2) | EP1801121A1 (https=) |
| JP (1) | JP5390191B2 (https=) |
| AT (1) | ATE471945T1 (https=) |
| AU (1) | AU2006328909A1 (https=) |
| CA (1) | CA2633213A1 (https=) |
| DE (1) | DE602006015103D1 (https=) |
| ES (1) | ES2347694T3 (https=) |
| WO (1) | WO2007071449A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1873166T3 (da) | 2006-06-30 | 2010-12-20 | Conaris Res Inst Ag | Forbedrede sgp 130Fc-dimerer |
| EP2174667B1 (en) * | 2007-07-26 | 2017-01-04 | Osaka University | Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient |
| EP2050759A1 (en) * | 2007-10-19 | 2009-04-22 | CONARIS research institute AG | Soluble gp 130 muteins with improved binding activity |
| RS65665B1 (sr) | 2014-12-01 | 2024-07-31 | Ferring Bv | Selektivne kompozicije inhibitora il-6-trans-signalizacije |
| LT3226888T (lt) | 2014-12-01 | 2021-05-25 | Ferring B.V. | Selektyvaus il-6-trans-signalinio inhibitoriaus skyrimas |
| US20190002915A1 (en) * | 2015-12-14 | 2019-01-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulatable antibody expression |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994012520A1 (en) * | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| CA2344277A1 (en) * | 1998-09-22 | 2000-03-30 | University Of Maryland, Baltimore | Cystine knot growth factor mutants |
| CZ20012406A3 (cs) * | 1999-01-07 | 2002-03-13 | Lexigen Pharmaceuticals, Corp. | Exprese a export proteinů působících proti obezitě jako Fc fúzních proteinů |
| EP1148065B1 (en) * | 2000-04-21 | 2008-01-02 | CONARIS research institute AG | Fusion proteins comprising two soluble gp130 molecules |
| ES2302845T3 (es) * | 2001-10-19 | 2008-08-01 | Zymogenetics, Inc. | Factor de crecimiento dimerizado y materiales y metodos para producirlo. |
| EP1491554A1 (en) * | 2003-06-23 | 2004-12-29 | CONARIS research institute AG | PEGylated soluble gp130-dimers useful as a medicament |
| JP2008504012A (ja) * | 2004-01-28 | 2008-02-14 | シントニックス・ファーマシューティカルズ・インコーポレーテッド | 不妊治療のためのへテロ二量体卵胞刺激ホルモン−Ｆｃ（ＦＳＨ−Ｆｃ）融合タンパク質 |
-
2005
- 2005-12-23 EP EP05028420A patent/EP1801121A1/en not_active Withdrawn
-
2006
- 2006-12-22 EP EP06841152A patent/EP1994053B1/en active Active
- 2006-12-22 WO PCT/EP2006/012515 patent/WO2007071449A1/en not_active Ceased
- 2006-12-22 AU AU2006328909A patent/AU2006328909A1/en not_active Abandoned
- 2006-12-22 AT AT06841152T patent/ATE471945T1/de not_active IP Right Cessation
- 2006-12-22 DE DE602006015103T patent/DE602006015103D1/de active Active
- 2006-12-22 ES ES06841152T patent/ES2347694T3/es active Active
- 2006-12-22 JP JP2008546287A patent/JP5390191B2/ja active Active
- 2006-12-22 US US12/158,285 patent/US7851182B2/en active Active
- 2006-12-22 CA CA002633213A patent/CA2633213A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2633213A1 (en) | 2007-06-28 |
| WO2007071449A1 (en) | 2007-06-28 |
| DE602006015103D1 (de) | 2010-08-05 |
| AU2006328909A1 (en) | 2007-06-28 |
| JP5390191B2 (ja) | 2014-01-15 |
| US7851182B2 (en) | 2010-12-14 |
| EP1994053B1 (en) | 2010-06-23 |
| JP2009520480A (ja) | 2009-05-28 |
| EP1801121A1 (en) | 2007-06-27 |
| US20090227499A1 (en) | 2009-09-10 |
| ES2347694T3 (es) | 2010-11-03 |
| EP1994053A1 (en) | 2008-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Scalise et al. | The human SLC7A5 (LAT1): the intriguing histidine/large neutral amino acid transporter and its relevance to human health | |
| Schiraldi et al. | HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4 | |
| UA117216C2 (uk) | Пухлиноасоційований пептид та його застосування | |
| Tan et al. | Tyrosine sulfation of chemokine receptor CCR2 enhances interactions with both monomeric and dimeric forms of the chemokine monocyte chemoattractant protein-1 (MCP-1) | |
| Yates-Binder et al. | An IP-10 (CXCL10)-derived peptide inhibits angiogenesis | |
| Hovanessian | Midkine, a cytokine that inhibits HIV infection by binding to the cell surface expressed nucleolin | |
| EA200801166A1 (ru) | Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа | |
| TW200730539A (en) | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 | |
| EA200801460A1 (ru) | Рекомбинантные моновалентные антитела и способы их получения | |
| JP2008500025A5 (https=) | ||
| ATE473759T1 (de) | Bifunktionelle moleküle sowie darauf basierende therapien. | |
| CO6390070A2 (es) | Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas incluyendo receptor de factor de crecimiento tipo insulina -i | |
| ATE457728T1 (de) | Kristallstruktur des aurora-2 proteins und dessen bindungstaschen | |
| JP2015514393A5 (https=) | ||
| HRP20050416A2 (en) | Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives | |
| BRPI0508670A (pt) | proteìnas de buganina modificada, citotoxinas e métodos e usos delas | |
| ATE471945T1 (de) | Als medikament geeignete lösliche varianten des gp130-moleküls | |
| Voltà-Durán et al. | Controlling self-assembling and tumor cell-targeting of protein-only nanoparticles through modular protein engineering | |
| Gironda-Martínez et al. | Identification and validation of new interleukin-2 ligands using DNA-encoded libraries | |
| EA202193040A1 (ru) | Конъюгат анти-всма антитела, композиции, содержащие данный конъюгат, и способы его получения и применения | |
| BRPI0407031A (pt) | Composições e métodos para tratamento de câncer empregando igsf9 e liv-1 | |
| Ensenberger et al. | Specific interactions between F1 adhesin of Streptococcus pyogenes and N-terminal modules of fibronectin | |
| Jouffroy et al. | Development of a concise and robust route to a key fragment of MCL-1 inhibitors via stereoselective defluoroborylation | |
| JP2008539795A5 (https=) | ||
| Schauenburg et al. | Peptide Bispecifics Inhibiting HIV-1 Infection by an Orthogonal Chemical and Supramolecular Strategy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |